Last reviewed · How we verify
NCT03800693
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Phase 2 trial testing Fluorouracil in Malignant Digestive System Neoplasm in 60 participants. Currently enrolling.
5 August 2026
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 14 March 2019 |
| Primary completion | 5 August 2026 |
| Estimated completion | 17 September 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Fluorouracil — full drug profile →
- Leucovorin (leucovorin) — full drug profile →
- Oxaliplatin (Oxaliplatin) — full drug profile →
Conditions studied
- Malignant Digestive System Neoplasm — all drugs for Malignant Digestive System Neoplasm →
Sponsor
Emory University
Who can join
18 and older, any sex, with Malignant Digestive System Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03800693
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluorouracil
Trials testing the same drug.
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
- NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
- NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
- NCT07456852 — Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Ca · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Malignant Digestive System Neoplasm
Currently open trials in the same condition.
- NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
- NCT06855524 — Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer · Phase 2 · recruiting
- NCT04986566 — Perioperative Telemonitoring to Optimize Cancer Care and Outcomes · NA · active not recruiting
- NCT04111172 — A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma · Phase 2 · active not recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03800693 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 6 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800693.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing